Maruti Suzuki India is India's largest passenger vehicle manufacturer and largest passenger vehicle exporter, with a product range spanning small cars, sedans, SUVs and the e VITARA electric SUV. The company's economics rest on scale, a deeply localised supplier base, a large sales and service network and Suzuki's global distribution. The current investment question is whether 500,000 units of capacity added in H1 FY27 convert a strong GST-driven order book into revenue and margin, or whether commodity costs, export weakness and start-up depreciation keep profit conversion below the volume recovery.
Q2 FY27 showed unusually strong demand. Domestic wholesale grew 37.8% year-on-year to over 5.65 lakh units, total volume rose 26.5% to a record 696,654 units, and domestic market share rose 2.2 percentage points to 40.8%. The 18% GST small-car portfolio grew 35.9% and the 40% GST portfolio grew 39.6%, so the recovery was broad. Pending orders were about 200,000 at end-September and about 270,000 by 20 October, while network inventory was only about 17 days. That is not a normal cyclical upturn with excess stock; it is a supply-constrained franchise with visible demand.
The supply constraint has now been addressed physically. Maruti added 500,000 units of annual capacity in H1 FY27: a new 250,000-unit Kharkhoda line in H1 and the fourth 250,000-unit Hansalpur line in Q2. Management says both are progressively ramping. This is the central operating-leverage mechanism. The prior constraint was production, not demand; the new lines allow Maruti to convert pending orders into wholesales and absorb fixed costs. The Q2 call also indicates the capacity was added without waiting for a demand recovery, which is the right sequence for an operating-leverage thesis, but the profit proof is not yet complete.
Q2 financials show the gap between volume and profit. Net sales were the highest ever at over INR 506 billion, but EBIT was over INR 28 billion versus over INR 33.8 billion a year earlier, and net profit was over INR 24 billion versus about INR 33 billion. The EBIT decline was attributed to West Asia conflict-linked commodity increases. The net profit decline was worsened by mark-to-market losses on the invested surplus, which cut non-operating income. Sequentially, however, EBIT rose 10.8% from Q1 to Q2, and EBITDA margin improved to 9.4% from 8.6%. The sequential bridge showed higher selling prices worth about 80 bps, cost reduction 20 bps, fixed-cost absorption 60 bps and lower employee cost 30 bps, partly offset by commodity 30 bps, forex 40 bps, other expenses 50 bps and depreciation 30 bps. That is a real operating improvement, but it is not yet a full margin cycle.
Management's guidance is specific on volume and vague on margin. It guides at least 10% domestic volume growth in H2 FY27 and overall growth of 7-10% with exports almost flat. It also affirmed full-year growth close to mid-teens versus about 10% earlier, though the transcript labels that response as operator, so the mid-teens figure should be treated as ambiguous. No forward margin guideline was given. Management has taken three price tranches amounting to a little over 1% and says calibrated pricing actions will continue in H2. It is concerned about steel and copper and calls steel price increases unjustified opportunism from the MIP policy. The near-term margin path therefore depends on commodity stability and cost control, not on a committed price-led recovery.
Exports are the main offsetting weakness. Q2 exports fell about 2% to 108,119 units on West Asia logistics and shipping volatility. Maruti still contributed more than 51% of India's passenger vehicle exports in H1 FY27, and the Fronx crossed 200,000 exports in under 38 months. But management now hopes only to be at least equal to last year, not too much better, citing Mexico raising duty from 20% to 50%. The e VITARA Europe ramp was disrupted by a product and production-line changeover plus regulatory changes such as e-call and carbon battery passport; management expects resumption in a couple of months. Exports are therefore a stabiliser, not the primary growth engine in FY27.
The product pipeline supports the mix. The new Brezza received a strong response, with about 35% of bookings for the 1-litre turbo petrol variant and 35% for underbody CNG. The new Baleno adds Level 2 ADAS, ventilated front seats, a Clarion sound system and the Z12e powertrain. Auto gear shift availability was expanded across Swift, Dzire and Baleno. Management plans one EV launch at the Bharat Mobility Show next year and says EVs will gradually move into smaller segments. On CAFE, it claims multi-powertrain flexibility across EVs, strong hybrids, other hybrids, biofuels, flex fuel and CNG, with CO2 15-25% lower than the nearest peer. These are supportive, but they are product refreshes and future launches rather than current profit drivers.
Capital allocation evidence is limited in the Q2 call. The 500,000 units of capacity are the main deployed capital, and the prior tracker had INR 14,000 crore of FY27 capex and a 4 million-unit medium-term capacity target. The Q2 call did not update either figure, so they remain prior commitments rather than current confirmation. The mark-to-market loss on the invested surplus confirms a large investment book, but the call does not provide debt, return on capital or funding details. The thesis should not assume a capital-allocation outcome that the transcript does not support.
Management delivery is mixed but improving. The April 2026 capacity promise was delivered on operationalization. The volume guide has firmed to at least 10% domestic growth in H2, with a possible full-year mid-teens outcome. The claim that start-up costs would not be significant is still open because Q2 depreciation and other expenses rose. Export guidance has been maintained, not raised. The 10% EBIT margin by 2030 was not restated. On the evidence available, management is delivering the physical build-out and the demand-side guidance, while the margin and export promises remain to be proven.
The operating-leverage thesis therefore remains intact but narrower than a simple volume-recovery story. The company has the capacity, the order book and the market share to grow volume. What is not yet proven is that the incremental volume earns a better margin. The key milestones are: progressive ramp of the Kharkhoda and Hansalpur lines; H2 domestic volume growth of at least 10%; overall growth of 7-10% with exports flat; EBITDA margin holding near 9.4% as steel and copper costs flow through; and e VITARA Europe normalising in a couple of months. The falsifiers are equally clear: H2 domestic growth below 10%, a falling order book, EBITDA margin slipping below the Q2 level, a sharper export decline from Mexico duty or logistics, a longer e VITARA Europe delay, or further mark-to-market losses that keep net profit below operating performance.
companyname: Maruti Suzuki India Limited ticker: MARUTI sector: Automobile Manufacturing Maruti Suzuki India Limited is India's largest passenger vehicle manufacturer and the country's largest exporter of passenger vehicles. Established in 1981 as a joint venture between the Government of India and Suzuki Motor Corporation (SMC) of Japan, the company became a subsidiary of SMC in 2002. As of 31 March 2026, SMC holds 58.53% of its equity stake. The company's shares trade on the National Stock Ex...
Read the full report →capex, market share gain
Management explicitly guides at least 10% domestic volume growth in H2 FY27 and overall growth of 7-10% with exports almost flat. It affirmed full-year growth close to mid-teens versus about 10% earlier, though that response is labelled Operator in the transcript. No forward margin, capex or medium-term numeric industry guidance was given.
Guidance maintainedoverdeliver
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Maruti Suzuki India Limited and 4,900+ companies.
5-day free pass. No card required.